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            Amendments from Version 1
Valuable input from all the reviewers has been taken into account 
in the improved second version of the manuscript. Major 
clarifications have been added to figure captions, with Figure 2 
and Figure 4 being revised. Several sections of the manuscript 
have been changed to improve the clarity and readability, and the 




Serious infections are common in children, especially those with 
severe acute malnutrition (SAM) admitted sick to hospitals, with 
over 50% of patients estimated to be infected at any one time1,2. 
Mortality remains high in this patient group, despite implemen-
tation of current treatment guidelines3. Although empiric antibi-
otics are routinely given4–7, it is not clear whether the currently 
recommended regimen is the most effective in the context 
of increasing antimicrobial resistance (AMR), and moreover 
whether expected therapeutic levels are achieved in this group of 
patients.
To resolve this question, a large clinical trial of metronidazole 
(MET) and ceftriaxone (CEF) versus standard care (penicillin or 
ampicillin plus gentamicin) is planned. However, first, a study of 
the pharmacokinetics (PK) of MET and CEF is needed in order 
to optimize the dosing strategy in severely malnourished children, 
since they may have altered absorption, body composition, volume 
of distribution, available plasma proteins for binding, or metabo-
lism and elimination through hepatic and renal pathways8,9. A quan-
titative determination of MET and CEF in plasma is essential in 
order to evaluate the pharmacokinetics of these co-administrated 
antibiotics (Figure 1).
Previous studies have indicated the activity of MET and its two 
principle metabolites, 1-(2-hydroxyethyl)-2-hydroxymethyl-5-
nitroimidazole (the “alcohol” metabolite, MET-OH) and 2-methyl-
5-nitroimidazole-1-acetic acid (the “acid” metabolite) against a 
broad range of anaerobic bacteria10,11. In this study however, we 
focus on the major active metabolite (the “alcohol” metabolite). 
Several methods have been reported for quantification of either 
MET12–15 or MET and its metabolites11,16 in human plasma or serum. 
O’Keefe et al.11 evaluated the activity of the metronidazole metab-
olites against anaerobic bacteria; however, the LC-UV method 
was limited in quantifying lower levels of the metabolites in a 
biological matrix due to its low sensitivity and poor selectivity. 
Silva et al.12 developed an HPLC-MS-MS method for the quan-
titation of metronidazole in plasma. The method required large 
sample volumes and complex sample preparation steps, with large 
volumes of extraction solvents.
CEF, like other β-lactam antibiotics, is highly protein bound. 
Wong et al.17 reported average protein binding of 89.5%. It has 
also been noted that ceftriaxone protein binding is nonlinear, 
becoming saturated at higher concentrations and linked with serum 
albumin concentrations in critically ill patients18. 
Figure 1. Chemical structures of ceftriaxone (A), metronidazole (B), hydroxymetronidazole (D) and cefuroxime axetil, IS (C).
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Given the significant effects of protein binding on clinical expo-
sure to highly bound drugs17,19–23, and given that the free drug is 
important for antimicrobial effect, it was necessary to develop a 
method to measure the unbound ceftriaxone appropriate for use in 
seriously ill malnourished children. Some of the methods reported 
previously24,25 give approaches to measurement of unbound frac-
tions of compounds using equilibrium dialysis, which are more 
prone to environmental interference and much more laborious in 
sample preparations. Other methods involved the use of HPLC 
with UV detection, but did not consider the protein binding of 
CEF26–29.
We aimed to develop the first simultaneous HPLC-ESI-MS/MS 
method for rapid, simple, reliable, sensitive and selective quan-
titation of MET, CEF and MET-OH in a small volume (50 µL) 




Ceftriaxone sodium (CEF; batch no. 3.2, purity 90.4%; 
MW=554.58 g/mol), metronidazole (MET; batch no. 2.1, purity 
100%, MW=171.15 g/mol) and cefuroxime axetil (CEFU, batch 
no. 4.0, purity 97.3%, MW=510.47 g/mol) were purchased from 
European Directorate for the Quality of Medicines and Health-
care (Strasbourg, France). Hydroxymetronidazole (MET-OH; 
Lot no. 4276, purity 98.2%, MW=187.15 g/mol) was purchased 
from LGC (Teddington, UK). Acetonitrile and methanol (both 
LC-MS grade), formic acid (85%; AnalaR®grade) and ammonium 
formate (AnalaR®grade) were purchased from Sigma Aldrich 
(St. Louis, MO, USA). Deionized water was prepared using a 
Smart2 PureTM water purification system (Thermo-scientific, 
Niederelbert, Germany). Blank human plasma with Li-heparin for 
the preparation of calibrators and quality controls was obtained 
from Kenya Medical Research Institute, Centre for Clinical 
Research (Nairobi, Kenya). The matrix used to quantify free 
fraction of ceftriaxone was plasma ultrafiltrate obtained by 
ultrafiltration of drug-free plasma.
Sample preparation
Total drug. To a 50 µL aliquot of plasma (blank, standard, 
quality control, or patient sample) 200 µL of internal standard 
(CEFU; of a 1.25 µg/mL solution in acetonitrile) was added. The 
1.5 mL polypropylene tubes were vortex-mixed for 3 minutes 
to precipitate the plasma proteins, followed by centrifugation 
(4000 x g; 10 min, 4°C). The supernatant (100 µL) was transferred 
into another clean 1.5 mL polypropylene tube and diluted with 
400 µL of 20% methanol in water. The samples were vortex- 
mixed for 3 minutes and submitted for analysis by LC-MS/MS.
Unbound ceftriaxone. About a 300 µL aliquot of patient 
plasma was taken into a clean 1.5 mL polypropylene tube and incu-
bated on a Grant JB Series incubation bath (Grant Instruments, 
Cambridge, UK) at 37°C for 1 h, then transferred into Centrifree® 
Ultrafiltration Device (Merck Millipore Ltd, Darmstadt, Germany) 
and centrifuged on a Thermo Fisher Scientific SL 40R centrifuge 
(2000 x g; 30min, 37°C). 25 µL sample ultra-filtrate was taken 
into another clean 1.5 mL polypropylene tube; internal standard 
solution (200 µL, 1.0 µg/mL) in acetonitrile was added to the 
sample and diluted to 1 mL with 20% methanol in water. The 
samples were vortex-mixed for 3 min and submitted for analysis 
by LC-MS/MS. Calibrators and quality control (QC) samples were 
prepared by ultrafiltration of blank plasma after 1h incubation at 
37°C, 200 µL aliquots the ultrafiltrate were spiked with 50 µL of 
CEF working solutions to produce 0.4, 12, 24, 48, 96, 150, 220, 
300 µg/mL CEF and 1.2, 120, 240 µg/mL QCs.
Preparation of analytical standards
Stock solutions of CEF (5 mg of the base/mL), MET and MET-
OH (both 1 mg/mL) were prepared by dissolving an appropriate 
amount of each compound in 20% methanol. The stock solutions 
were further serially diluted with 20% methanol to make working 
standard solutions used to spike the blank plasma to produce 0.4, 
12, 24, 48, 96,150,220, 300 µg/mL CEF and 1.2, 120, 240 µg/mL 
QCs; 0.05, 1.0, 2.0, 4.0, 8.0, 16.0, 32.0, 50 µg/mL MET and 0.15, 
20, 40 µg/mL QCs; 0.02, 0.8, 1.6, 3.2, 6.4, 13, 20, 30 µg/mL 
MET-OH and 0.06, 12, 24 µg/mL QCs. Stock solution of CEFU 
(IS) was prepared by dissolving appropriate amount of the 
compound in acetonitrile, the stock solution was serially 
diluted with acetonitrile to make working standard solutions of 
1.25 µg/mL and 1 µg/mL. All the stock solutions were stored 
at -20°C, protected from light (in amber sample vials) and used 
within three months.
Chromatographic conditions
The equipment consisted of an Agilent Technologies HPLC-ESI-
MS/MS system (Santa Clara, CA, USA), composed of a 1260 µ 
Quaternary Pumps, 1260 Autosampler and 1260 Thermosetting 
Column Compartment (TCC). Chromatographic separation was 
performed on a Polaris 5 C18-A (150 mm x 3.0 mm I.D; 3.0 µm 
particle size) analytical column from Agilent Technologies (Santa 
Clara, CA, USA) with a C18 guard cartridge (4 mm x 3.0 mm, 
3.0 µm) (Phenomenex, Torrance, CA, USA) maintained at 30°C. 
The mobile phase consisted of (A) 10mM aqueous ammonium 
formate pH 2.5 and (B) 0.1% formic acid in acetonitrile. A linear 
gradient elution was used to deliver the mobile phase, 40% solvent 
B at time 0 min, and 100% from 1.8 min, to 5.5 min, and back to 
40% from 6 min to 12 min, (re-equilibration step). The flow rate 
was set at 300 µL/min, an injection volume of 5 µL was used to 
optimize the drug signals and for analysis.
Mass spectrometry
Mass spectrometric detection of analytes was performed on a 
6410 Triple Quadrupole Mass Spectrometer with an Electrospray 
Ionization (ESI) source from Agilent Technologies (Santa Clara, 
CA, USA) in positive ionization mode. Nitrogen was used as the 
nebulizing, desolvation and collision gas, the optimized ion source 
parameters were: ion spray voltage 4.0 kV, exit potential 7V, RF 
lens 0.5 V.
Source temperature was 100°C and desolvation temperature 
300°C. High purity nitrogen from Genius NM32LA generator (Peak 
Scientific, Scotland, UK) was used as both sheath and auxiliary gas 
set at 20 l/min and 12 l/min, respectively.
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Multiple reaction monitoring (MRM) was employed for the data 
acquisition, the analytical parameters optimized for the compounds 
were declustering potentials (DP) and collision energies (CE) 
(Table 1), and the scan dwell time was set at 500 ms. for each 
channel. Data acquisition and analysis were accomplished with 
Mass Hunter software (version A.02.00; Agilent Technologies).
Validation
Method validation was performed as per the US Food and Drug 
Administration Guidance for Industry Bioanalytical Method 
Validation30. The method was validated for selectivity and sensi-
tivity, inter-day and intra-day accuracy and precision, extraction 
recovery, matrix effect and stability. Method’s linear range was 
evaluated and lower limit of quantification was set to fit for pur-
pose for the actual clinical trial samples. Carry-over was assessed 
in accordance with the European Medicines Agency guideline31.
Selectivity of the method was assessed and assured by analysis 
of six blank plasma samples from different sources, each blank 
sample was tested for interference using the proposed extraction 
procedure and chromatographic/mass spectrometric conditions 
and compared with those obtained with an aqueous solution of 
the analyte at a concentration near to the lower limit of quantifi-
cation (LLOQ). A plasma sample fortified with cefadroxil and 
cefaclor was also processed and analyzed.
ExtractionThe standard curves were obtained through analysis 
of calibration standard plasma and ultra-filtrate (for free CEF) 
samples and plotting of peak area ratio of MET, CEF and ME-OH 
versus the corresponding nominal concentrations. The linearity 
of the standard curves were evaluated using least-squares linear 
regression analysis.
The analytical extraction  recovery was determined by compar-
ing the response of extracted quality control plasma samples with 
the response of post extracted plasma samples spiked at similar 
concentrations to the quality control samples.
To evaluate the inter-assay precision and accuracy, six replicates 
of quality control plasma samples were analyzed together with 
one independent calibration standard curve, this was done in three 
consecutive days; while intra-assay precision and accuracy were 
evaluated through analysis of quality control plasma samples 
in replicate of six in the same day. Inter-assay and intra-assay 
precision were expressed as coefficient of variation (CV%).
The accuracy was expressed as the percent ratio between the 
experimental concentrations and the nominal concentration for 
each sample. A similar assessment was done for plasma ultra- 
filtrate to determine the accuracy and precision for the unbound 
ceftriaxone.
Stability (ST%) studies were evaluated via sample and solution 
concentrations, where:
	 	 				 0
=  ×100%.tcST%
c 	 							 										
(i)
ST% is the stability of the chemical compound in the sample 
over the period of time. c0 is the initial concentration, determined 
without introducing any extra pauses in the analysis process. c
t
 is 
the concentration obtained after the storage period with time t.
Sub-stock solution stability was evaluated for CEF, MET and 
MET-OH, by comparing the response generated from the same 
solution at preparation and after being stored at -20°C for a 
period of 28 days. All the analytes were found to be stable within 
the period investigated and fresh stock solutions were prepared 
thereafter, fresh IS solution was prepared daily from weighing 
during the method validation and study samples analysis. The 
stability was reported as coefficient of variation between the 
initial concentration and the concentration at day 28.
Spiked plasma samples were subjected to three freeze-thaw cycles 
at -20°C and the analytes concentrations assessed after the third 
cycle. This was done also for plasma ultra-filtrate spiked with CEF 
to assess the stability of free ceftriaxone in calibrators and quality 
control samples.
Bench-top stability was evaluated by keeping plasma samples 
at low and high quality control levels at ambient temperatures 
(< 28 °C) for at least 8h then processed and analyzed. Selected 
ambient temperature covered the temperature range for study 
samples, as ambient temperatures remained < 28°C.
Processed sample stability was assessed by letting the samples 
stay in the autosampler at 18°C for 24h and then they were 
analyzed the following day. This was done to ensure data integrity 
in case of equipment failure and initiation of a re-run.
Long term stability of the analytes was studied over a period 














CEF [M+H]+ 555.1→ 396.0 60 18
MET [M+H]+ 172.2→ 128.2 100 15
MET-OH [M+H]+ 188.0→ 125.9 100 15
CEFU [M+NH4]
+ 528.1→ 364.0 60 18
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collection to the last sample analysis, this ensured that the 
integrity of study samples was not compromised over the period 
of storage. To investigate long term stability, two sets of sample 
aliquots were prepared at concentrations corresponding to low and 
high quality control levels. The first set was processed and ana-
lyzed at day 1 and the second set after 90 days of storage at -20°C. 
The analyte concentrations in the plasma and ultra-filtrate 
samples at 90 days of storage was compared with those obtained on 
day 1 to determine the percentage stability.
To assess carry-over, a processed blank sample was injected after 
a high concentration calibration standard at the upper limit of 
quantification (ULOQ) and the peak response in blank sample 
determined.
Two different methods were used to access and determine 
matrix effect. In the first method, regions of ion suppression or 
enhancement were evaluated by direct post column infusion of 
a mixture of analytes and IS at high concentration at the rate of 
10 µL/min, while injecting a blank extracted plasma. In the 
second method, matrix effect (ion enhancement) was evaluated 
for MET in six different lots of plasma by comparing the 
response of post extracted plasma samples spiked with 
0.15 µg/mL (LLOQ) and 40 µg/mL (ULOQ) of metronidazole 
with the response of neat standard solutions spiked at similar 
concentrations.
Incurred sample reanalysis was done 90 days after the initial study 
sample analysis. A subset of subject samples (25 samples) were 
selected from randomly picked study participants and analyzed 
against freshly spiked calibrators and QCs. The percentage varia-
tion in the two analyses were determined by:






        
(ii)
Where: Variation% is the percentage difference between the 
initial analysis and the reanalysis concentrations, Rc is the 
repeat analysis concentration measured, Oc is the initial analysis 
concentration measured, Mc is the mean of the initial and repeat 
analysis concentrations.
Results and discussion
Method development and chromatographic separation of 
the analytes
Ceftriaxone is an acidic compound possessing a β-lactam ring in 
its structure (Figure 1A). Like many β-lactam antibiotics, CEF is 
more susceptible to chemical and biological degradation due to its 
labile β-lactam ring32,33. Metronidazole on the other hand is slightly 
basic and fairly resistant to degradation34,35. This work is unique 
and novel, designed to develop a method that would be useful in 
simultaneous assay of CEF, MET and MET-OH from only 50 µL of 
human plasma, and unbound CEF from 25 µL plasma ultra-filtrate 
based on the physicochemical properties of these compounds and 
the area of method application. Moreover, the concerns raised by 
Berezhkovskiy et al.22 on temperature dependency of protein bind-
ing and the need to maintain the physiological temperature (37°C) 
through the sample processing time were considered in sample 
pretreatment.
The method took into account the therapeutic and overdose 
concentration ranges. The method has been validated and proved 
to be reliable for the determination of the drugs in human plasma. 
During the method development, several chromatographic 
conditions were optimized for all analytes such as the mobile phase 
composition, pH and various flow rates. Various ratios (80:20, 
70:30, 60:40 v/v) of acetonitrile and 10 mM ammonium formate 
were tested as starting eluent for chromatographic separation. The 
variation in the mobile phase led to considerable changes in the 
chromatographic parameters, like peak symmetry and retention 
time. The pH effect showed that optimized conditions are reached 
when the pH value of the buffer is adjusted to 2.5 with formic acid, 
producing well resolved and sharp peaks for all analytes assayed. 
Henceforth, in the present method the pH adjusted to 2.5 and the 
chosen LC gradient ensured sharp chromatographic peaks with 
the best possible baseline-resolved separations of CEF, MET, 
MET-OH and CEFU (IS) within 4 minutes with a total runtime 
of 12 minutes. With the optimized MRM transitions, the stable 
and most intense product ions of CEF (m/z 396.0), MET 
(m/z 128.2), MET-OH (m/z 125.9) and CEFU (m/z 364.0) were 
detected (Figure S1).
Method validation
Selectivity. All the lots of blank plasma used for selectivity studies 
met the acceptance criteria, no significant interferences at the 
retention times of the analytes or internal standard were found. 
Figure 2 shows the typical chromatograms of extracted blank 
plasma, blank plasma spiked with IS (Zero sample), a spiked 
plasma sample with the analytes at LLOQ and ULOQ level. It 
can be seen that there were no interfering peaks from endogenous 
compounds observed at the retention times of the analytes and 
the IS. Moreover, no interference was observed from plasma 
samples fortified with commonly used β-lactam antibiotics 
(cefadroxil and cefaclor), processed and analyzed as described 
under the proposed sample preparation procedure.
Calibration curves and limit of quantification. Calibration 
curves were constructed by plotting peak area ratios of analytes 
and IS against the nominal concentrations of CEF, MET and 
MET-OH. The curves for drugs spiked in plasma were found to 
be linear over the concentration ranges of 0.4–300 µg/mL (CEF), 
0.05–50 µg/mL (MET) and 0.02–30 µg/mL (MET-OH). A weighted 
(1/x2) linear regression model was used due to the wide range of 
concentrations covered by the calibration graphs. The choice of 
this regression model was based on all available data from the 
validation phase, in light of this the method proved to be reliable 
in terms of accuracy and reproducibility over the entire calibra-
tion range (Table S1). The coefficients of variation of the slopes of 
six calibration curves were 9.8% (MET), 9.4% (CEF), 6.7% 
(MET-OH) and 7.2% (CEF in ultra-filtrate). The LLOQs for the 
method were set by the needs of the clinical trial. The LLOQ is the 
lowest standards on the calibration curve that the method is able to 
identify and whilst still providing discrete and reproducible results 
with a precision ≤ 20% and accuracy within 80%–120% (Table 2). 
The limits of detection (LODs) were determined as the lowest 
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Figure 2A. Representative chromatograms from extracted zero sample (with IS only), cefuroxime (RT 3.71 min).
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Figure 2B. Representative chromatograms of ceftriaxone (RT 2.59 min), metronidazole (RT 2.67 min), hydroxymetronidazole (RT 2.69 
min), and cefuroxime (IS) (RT 3.71 min) from extracted spiked plasma at LLOQ. 
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Figure 2C. Representative chromatograms of ceftriaxone (RT 2.59 min), metronidazole (RT 2.67 min), hydroxymetronidazole (RT 2.69 
min) and cefuroxime (IS) (RT 3.71 min) from extracted spiked plasma at ULOQ.
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MET 0.05 0.051 ± 2.0 3.9 101.9
0.15 0.148 ± 7.7 7.8 98.7
20 20.44 ± 4.0 3.9 102.2
40 37.75 ± 5.6 5.9 94.4
CEF 0.4 0.39 ± 2.5 3.2 97.5
1.2 1.10 ± 1.5 1.7 91.7
120 112.02 ± 3.5 3.7 93.3
240 219.51 ± 6.8 7.5 91.5
MET-OH 0.02 0.018 ± 1.7 2.6 90.0
0.06 0.057 ± 4.7 4.9 95.0
12 11.43 ± 2.5 2.7 95.2
24 24.49 ± 8.6 8.4 102.0
CEFuf 0.4 0.41 ± 5.5 5.3 100.9
1.2 1.27 ± 5.5 5.2 105.8
120 112.32 ± 5.1 5.5 93.6
240 253.03 ± 8.2 7.8 105.4
Inter-assay 
(n=18)
MET 0.05 0.051 ± 1.4 2.7 101.1
0.15 0.155 ± 5.6 5.4 103.3
20 20.59 ± 3.3 3.2 103.0
40 38.79 ± 5.6 5.8 97.0
CEF 0.4 0.40 ± 2.7 2.9 100.0
1.2 1.15 ± 3.8 3.9 95.8
120 114.54 ± 5.1 5.4 95.4
240 226.75 ± 5.2 5.5 94.5
MET-OH 0.02 0.019 ± 1.2 2.3 95.0
0.06 0.059 ± 5.2 5.3 98.3
12 12.01 ± 4.8 4.8 100.1
24 24.51 ± 4.7 4.6 102.1
CEFuf 0.4 0.43 ± 5.8 7.4 107.2
1.2 1.22 ± 8.3 8.1 101.6
120 115.32 ± 5.1 5.3 96.1
240 251.30 ± 6.2 5.9 104.6
concentration of the analyte at which the signal to noise (S/N) ratio 
exceeded 3:130. ULOQ values were determined from anticipated 
peak concentrations ranges of the analytes, and ensuring that the 
calibration points met the accuracy and reproducibility criteria of 
method validation.
Extraction recovery. Protein precipitation with acetonitrile was 
used to extract the analytes and the IS from plasma samples, this 
method was found to be efficient given the small sample volume 
(50 µL) used that would otherwise be impossible to use with 
the liquid-liquid extraction techniques employed in previously 
reported publications12,13,15 for MET and26–29 for CEF. This still 
yielded higher recoveries with better reproducibility (Table S2).
Accuracy and precision. Accuracy of the method for the analytes 
in plasma were between 90.0%–105.5%, and precision, meas-
ured in CV%, was always lower than 8.5%, depicting the high 
precision of the method. The accuracy of the method for CEF in 
ultra-filtrate was between 93.6%–107.2% and a precision lower 
than 8.1% (Table 2).
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Table 3. Stability (ST%) of metronidazole (MET), ceftriaxone (CEF), hydroxymetronidazole (MET-OH) with the 
coefficient of variation (CV%) in plasma and CEF in ultra-filtrate (CEFuf) (n=5).
MET CEF MET-OH CEFuf 
Stability parameters Spiked conc. 
(µg/ mL)
0.15 40 1.2 240 0.06 24 1.2 240
Benchtop stability in matrix 
(room temperature, 8 h)
Mean of stability 
of samples
0.16 39.32 1.18 230.4 0.059 24.52 1.19 253.9
CV % 3.8 1.4 4.4 2.5 1.5 3.5 2.4 1.9
ST % 105.8 98.3 98.1 96.0 99.5 102.2 99.8 105.8
Freeze-thaw stability (3 
freeze-thaw cycles at -20ºC)
Mean of stability 
of samples
0.14 37.40 1.15 228.6 0.058 24.18 1.12 221.3
CV % 3.2 1.8 3.4 2.7 5.1 4.1 4.4 3.1
ST % 96.1 93.5 95.8 95.3 97.2 100.7 93.0 92.2
Auto-sampler stability  
(24 h at 18ºC)
Mean of stability 
of samples
0.15 37.50 1.09 228.9 0.062 22.27 1.18 226.1
CV % 3.3 4.3 5.7 5.4 5.0 5.6 7.1 9.6
ST % 101.5 93.7 90.6 95.4 103.3 92.8 98.4 94.2
Long-term stability  
(90 days at -20ºC)
Mean of stability 
of samples
0.14 37.52 1.11 217.4 0.059 22.08 1.13 221.8
CV % 6.0 4.7 4.2 7.3 1.4 5.6 3.1 5.6
ST % 95.2 93.8 92.2 90.6 99.1 92.0 94.4 92.4
Sub-stock solution stability 




Mean of stability 
of samples
47.89 288.39 28.63
CV % 3.1 2.8 3.4
ST % 95.8 96.1 95.4
Stability (ST%)
The results of all the stability studies obtained were well within the 
acceptable limits of accuracy (± 15%) and precision (CV ≤ 15%) 
(Table 3).
Sub-stock stability. All analytes indicated good stability at the 
storage temperature, 95.4–96.1% of the original concentration 
was found after storage period of 28 days.
Freeze and thaw stability. Freeze and thaw stability (Table 3) 
was  consistent with previously reported data by Silva et al.12 
and Ilomuanya et al.15 for MET stability. Ilomuanya et al.15 in 
his freeze/thaw cycle evaluations indicated that after the fourth 
freeze/thaw cycle the concentrations of MET was < 90%, 
suggesting that MET is not very stable after three freeze/thaw 
cycles. This is however the first reported ultra-filtrate stability data 
for CEF.
Short term stability or bench-top stability. Plasma samples at 
low and high quality control levels were kept at room tempera-
ture for a minimum of eight hours, then processed and analyzed 
(Table 3). Some studies have reported stabilities of metronidazole 
over a longer duration than in this method12,15. Our choice for the 
8 h period was to report an analytically relevant study under 
which the three drugs can be analyzed. The results indicated that 
the drugs were stable and therefore the sample processing 
procedure outlined within this method can be used to process 
large number of samples without the risk of sample degradation 
due to room temperature exposure.
Silva et al.12 reported the stability of MET over a period of 48h, 
the mean stability ranging between 93.6% – 100.6%. This stability 
data was in agreement with what we have reported in this method, 
however we report the first stability study of MET-OH and CEF in 
plasma ultra-filtrate.
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24 h stability in the autosampler. The results of post processing 
stability in Table 3 indicated that all the drugs were stable after 
24 h in the autosampler and the integrity of data obtained after such 
re-assay would not be questionable. Ilomuanya et al.15 reported the 
autosampler stability of MET for 72h, however the data reported 
showed that MET was stable up to 24h and at 72h, the stability 
was greatly reduced to 40.6%–58.7%.
Long term stability at -20°C. The stability data reported in this 
study show that all the analytes were stable (90.6%–99.1%) within 
the period investigated. Since the stability at -20°C was acceptable, 
there was no need to evaluate the stability at -80°C, as our aim was 
to report a method that is affordable to resource limited laboratories.
Carry-over. No significant peak indicating carry-over was 
detected.
Matrix effect (ME%). The protein precipitation method of 
sample preparation is known to be prone to matrix effect36,37. 
Chromatography of analytes or IS, as well as accuracy of the 
method may be affected by matrix effect, ion suppression or 
enhancement, due to co-eluting endogenous components.  The 
matrix effect assessment Figure S2A (iv) revealed that only MET 
showed interference (ion enhancement) at its retention time. 
The matrix effect encountered with this method (Table S3) was 
much lower than in the previously reported method15, this could 









ResponsePOEM is the average concentration of post extraction spiked 
matrix and ResponseNEAT is the average concentration of the analyte 
in a neat solution.
The samples were prepared at two concentrations and the 
matrix effect determined as 107.6% (0.15 µg/mL) and 102.1% 
(40 µg/mL), n=6 at both levels. The values obtained at both levels 
were above 100% indicating the plasma-induced ion enhancement 
on the analysis of MET and suggesting that the endogenous com-
pounds increased the signal intensity of the analyte in positive 
ESI mode. The effect of signal enhancement was higher at low 
concentration level.
Incurred sample reanalysis (ISR)
Incurred sample reanalysis conducted on 25 samples showed 
more than 67% had results within the accepted limits (< 20%) of 
variation. The mean variation of the analytes for the reanalysis were 
5.7% (MET), 7.4% (MET-OH) and 7.0% (CEF), therefore, the 
reported subject sample analyte concentrations can be considered 
reliable and a true representation of the drug levels at the respective 
sampling times. Since sample storage was in plasma form, it was 
not necessary to perform reanalysis on the plasma ultra-filtrate.
Application of the method to real patient samples
The Optimising Antibiotic Treatment for Sick Malnourished 
Children (FLACSAM-PK) study was registered (NCT02746276) 
at ClinicalTrials.gov38.
The validated method was successfully applied to a pharmacoki-
netic study of CEF, MET, MET-OH and unbound ceftriaxone in 
hospitalized children with complicated severe acute malnutrition 
(SAM) following an oral administration of MET and intravenous 
administration of CEF over the course of 72 hours. 
81 hospitalized children with SAM and requiring IV antibiotics 
according to WHO and national guidelines were recruited (after 
obtaining ethical approval from the Kenya Medical Research Institute 
Scientific and Ethics Review Unit, approval number: KEMRI/
SERU/CGMR-C023-3161 and informed consent from the 
parents/guardians) and treated with an oral dose of 7.5mg/Kg MET 
(Flagyl®oral suspension, 200 mg/5 mL) three times daily and IV 
injection of 80 mg/kg CEF (Ceftriaxone Rocephin®, 250 mg) once 
daily 15 min after metronidazole dose. Blood samples (3.0 mL) were 
collected into Li-heparinized tubes, a pre-dose sample was taken 
before administering the drugs. Further sampling at 5, 30, 60 min 
after ceftriaxone dose and 2, 4, and 8 h after metronidazole dose. 
The sampling plan was such that each patient had only three 
blood draws after the base-line sample. The blood was centrifuged 
(3000 rpm; 5 min), plasma separated and stored at -80°C until 
analysis time.
The patient samples were successfully analyzed using this 
method and no interference of endogenous compounds result-
ing from altered plasma protein compositions was encountered. 
Figure 3, shows a concentration–time profile of a baseline 
and three post-dose samples from a patient who had previ-
ously taken at least one metronidazole dose prior to study 
enrolment, this was evident from the significant levels of metro-
nidazole and hydroxymetronidazole detected from the baseline 
sample.
We also addressed the recommendations by Wong et al.17, as this 
method allows for direct measurement of unbound ceftriaxone 
from only 25 µL plasma ultra-filtrate. Figure 4 shows representa-
tive chromatograms of processed plasma samples from one of the 
study participants.
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Figure 3. Example concentration-time data of each of the four blood samples (baseline and 3 post first dose), where ceftriaxone, metronidazole 
and hydroxymetronidazole were quantified. In 2 samples, unbound ceftriaxone was also quantified. This example shows a patient who has 
clearly taken at least one previous dose of metronidazole prior to study enrolment.
Page 13 of 33
Wellcome Open Research 2018, 2:43 Last updated: 16 MAR 2018
Figure  4A.  Representative  chromatograms  from  processed  plasma  study  sample  at  baseline  before  drug  administration  with 
undetectable levels of the drugs..
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Figure  4B.  Representative  chromatograms  of  ceftriaxone  266.27µg/mL  (RT  2.59  min),  metronidazole  2.54µg/mL  (RT  2.67  min), 
hydroxymetronidazole 0.13µg/mL (RT 2.69 min) and cefuroxime (IS) (RT 3.71 min) from processed plasma study sample at 5 min after 
administering ceftriaxone IV. 
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Figure  4C.  Representative  chromatograms  of  ceftriaxone  74.39µg/mL  (RT  2.59  min),  metronidazole  1.99µg/mL  (RT  2.67  min), 
hydroxymetronidazole 0.66µg/mL (RT 2.69 min) and cefuroxime (IS) (RT 3.71 min) from processed plasma study sample at 30 min 
after administering ceftriaxone IV.
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Conclusions
The validated HPLC–ESI–MS/MS method allowed the simultane-
ous quantitation of metronidazole, hydroximetronidazole, ceftriax-
one from only 50 µL human plasma, and of unbound ceftriaxone 
from 25 µL plasma ultra-filtrate. It provided simple and rapid 
analyses, as well as sensitive and reliable results. Thus, this 
method is suitable for routine high-throughput analyses and may 
be successfully applied to pharmacokinetic and bioequivalence of 
multiple doses evaluated in the present work in human subjects. 
The small sample volumes used makes it applicable to pediatric 
pharmacokinetics and bioequivalence studies, in which large 
sample volumes maybe unethical or impractical to obtain.
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Response: Respectfully, it is true that both metabolites are pharmacologically active. The
major active metabolite however is the alcohol metabolite, we therefore measured the
metabolite that would cause a significant clinical effect on the patient. (Manuscript






This study involved analysis of samples from multiple dosing with the study drug, high
concentrations thus necessitated the large dilutions to levels optimal for MS detection. 
The method aimed at quantifying multiple drugs with varied physicochemical properties
simultaneously. Whereas use of mobile phase A looks conventional, it was tried and




Respectfully, whereas evaporating acetonitrile and reconstituting the residue could have
resulted into better sample purification, we were not keen to adopt that method since we
found it much laborious and time consuming. Furthermore the drug levels we anticipated
were high enough and pre-concentration was not our priority. 
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The equilibrium between the bound and free fractions of ceftraiaxone is temperature
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Manuscript changed to include the linearity domains for each molecule under preparation
of analytical standards.
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Figure 2A: Representative chromatograms from extracted zero sample (with IS
only), cefuroxime (RT 3.71 min) .Changes made to manuscript.
Figure 2B: Representative chromatograms of ceftriaxone (RT 2.59 min),
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 Figure 2B: Representative chromatograms of ceftriaxone (RT 2.59 min),
metronidazole (RT 2.67 min), hydroxymetronidazole (RT 2.69 min) and cefuroxime
(IS) (RT 3.71 min) from extracted spiked plasma at LLOQ .Changes made to
manuscript.
Figure 2C: Representative chromatograms of ceftriaxone (RT 2.59 min),
metronidazole (RT 2.67 min), hydroxymetronidazole (RT 2.69 min) and cefuroxime




The ULOQ values were determined from anticipated peak concentrations ranges of
the analytes, and ensuring that the calibration points met the accuracy and
reproducibility criteria of method validation. (Manuscript changed to include this in












Unbound ceftriaxone was measured at only 2 time points, the first time point was drawn 5
min after ceftriaxone iv administration (peak). The second time point was taken at the
trough (90 min) after drug administration. Protein binding of ceftriaxone is inversely
proportional to plasma concentrations, determining unbound ceftriaxone at the two time




Free ceftriaxone was measured at only 2 time points, the first time point was drawn 5 min
after ceftriaxone iv administration (not T0). The second time point was taken at the trough
(90 min) after drug administration. Baseline sample was not analyzed for free ceftriaxone
since no drug was anticipated at this point. 
The first time point for total ceftriaxone is a baseline sample and thus undetectable level
is expected. The 1  time point for total ceftriaxone therefore corresponds to the 2  time
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Figure 2B: Representative chromatograms of ceftriaxone (RT 2.59 min),
metronidazole (RT 2.67 min), hydroxymetronidazole (RT 2.69 min) and cefuroxime
(IS) (RT 3.71 min) from extracted spiked plasma at LLOQ .Changes made to
manuscript.
Figure 2C: Representative chromatograms of ceftriaxone (RT 2.59 min),
metronidazole (RT 2.67 min), hydroxymetronidazole (RT 2.69 min) and cefuroxime
(IS) (RT 3.71 min) from extracted spiked plasma at ULOQ. Changes made to
manuscript.
The LLOQ is defined under the sub-heading “Calibration curves and limits of
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 1.  
2.  
The LLOQ is defined under the sub-heading “Calibration curves and limits of
quantification” as the lowest standard on the calibration curve that the method is
able to identify and quantify discretely with a precision ≤ 20% and with an accuracy
within 80%-120%. No change made to manuscript.
2. Please indicate the spiked concentrations in figure 2C?
Response: The response in 1 above regarding Fig 2C addresses this.
3. Please indicate the quantified concentrations in Figure 4.
Response: Manuscript edited with additional information to include concentrations at the
sampling points as:
Figure 4A: Representative chromatograms from processed plasma study sample at
baseline before drug administration with undetectable levels of the drugs.
Figure 4B: Representative chromatograms of ceftriaxone 266.27µg/mL (RT 2.59
min), metronidazole 2.54µg/mL (RT 2.67 min), hydroxymetronidazole 0.13µg/mL (RT
2.69 min) and cefuroxime (IS) (RT 3.71 min) from processed plasma study sample
at 5 min after administering ceftriaxone iv.
Figure 4C: Representative chromatograms of ceftriaxone 74.39µg/mL (RT 2.59 min),
metronidazole 1.99µg/mL (RT 2.67 min), hydroxymetronidazole 0.66µg/mL (RT 2.69
min) and cefuroxime (IS) (RT 3.71 min) from processed plasma study sample at 30
min after administering ceftriaxone iv.
4. Please use true scale (intensity) instead of 100 % for all the figures.
Response: Figures have been changed as requested. 
 No competing interests were disclosed.Competing Interests:
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Is the rationale for developing the new method (or application) clearly explained?
Yes
Is the description of the method technically sound?
Partly
Are sufficient details provided to allow replication of the method development and its use by
others?
Partly
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
Partly
Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Partly
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that




Responses to the comments by Laurens Manning. 
1. The assay is being reported in the conclusion as a low volume assay, but 300µL is required for
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Response: This is a common misconception. For example, a 1ml sample taken at baseline
then 3 time points for an 8kg child represents 0.6% of blood volume (80ml/kg) and would









Response: I don’t think anyone should be doing PK studies if they cannot do the
separation soon after the blood was drawn. Our samples were immediately taken to labs
with AC in Kilifi & Mombasa and Nairobi. We can confirm that is room temperature
remained <28 degrees in all sites, therefore additional stability experiments are not





Response: Respectfully, we thought the chromatograms are best as represented for ease
of understanding and interpretation by the reader. Overlaid chromatograms would be
necessary with UV detection where overlapping peaks could be troublesome in




Response: MRM was employed as depicted from mass transitions in Table 1 and Figures
2 and 4. SRM was investigated during the early stages of compound optimization. The









Response: Respectfully, we acknowledge this as a recommendation rather than a critique
since the request is to have additional ‘sample child’ with a clear undetectable result at T0
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 since the request is to have additional ‘sample child’ with a clear undetectable result at T0
for comparability purposes and ease of interpretation. Full results of this study are being
published separately. 
 No competing interests were disclosed.Competing Interests:
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